Parexel’s Early Phase Clinical Unit (EPCU) in Berlin, Germany has collaborated with Clinical Trial Center (CTC) North to increase the research capacity for the delivery of Early Phase clinical trials.
CTC North is a full-service contract research organisation (CRO) located at the University Medical Center Hamburg-Eppendorf (UKE).
Through this strategic collaboration, the parties will support the high demand for and continuation of Early Phase clinical studies during the Covid-19 pandemic.
Enabling the optimal use of resources, the collaboration will provide additional bed capacity for healthy volunteers and patients ensuring continuation of early phase research.
As part of the collaboration, Parexel’s eSource system ClinBase will be rolled out and implemented at CTC North to drive efficiency and collaboration.
Berlin EPCU head Dr Sandra Stark said: “We’re delighted about the CTC North partnership, which leverages broad expertise across both partners to provide a unique solution for Clinical Pharmacology research in healthy volunteers and patients.
“The use of ClinBase as the eSource system will support trials from a data perspective resulting in minimal timelines for post-clinical services.”
Parexel’s Early Phase clinical development presence also includes EPCUs in Baltimore and Los Angeles (USA) and London (UK), providing access to over 300 beds and more than 35 patient populations.
Through this global network, customers will be able to run Phase I trials from multiple locations simultaneously with integrated technology to make real-time decisions.
Federal Association of Contract Research Organizations (BVMA) medical director and vice-president Ralf Freese said: “We’re pleased to have the opportunity to partner with Parexel’s Berlin EPCU after collaborating together for many years.”
